FDA peptide panel faces clash as Ebola outbreak kills over 1,000 and vaccine options remain limited

The FDA is holding a two‑day panel on peptide therapeutics, and observers anticipate heated debate among regulators and industry.

The African CDC reports the fastest‑growing Ebola outbreak, with more than 1,000 confirmed deaths from the Bundibugyo strain.

No vaccine or treatment is currently approved for this strain, though early studies suggest Merck’s vaccine for a related Ebola species might offer some protection.

The situation underscores urgent needs for funding, research, and regulatory pathways to address emerging infectious threats.